

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

^{Pr}**SEAFORD NIFEDIPINE AND LIDOCAINE HYDROCHLORIDE CREAM**

cream, 0.3%/1.5% w/w, rectal

Nifedipine: Calcium channel blocker,
ATC: C08CA05

Lidocaine: Local anesthetics,
ATC: C05AD01

Seaford Pharmaceuticals Inc.
29-1530 Drew Road
Mississauga ON, L5S 1W8

Date of Initial Authorization:
MAY 30, 2024

Date of Revision:
JUN 13, 2025

Submission Control Number: 293819

RECENT MAJOR LABEL CHANGES

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES 2

TABLE OF CONTENTS 2

PART I: HEALTH PROFESSIONAL INFORMATION 4

1 INDICATIONS..... 4

 1.1 Pediatrics..... 4

 1.2 Geriatrics..... 4

2 CONTRAINDICATIONS..... 4

3 SERIOUS WARNINGS AND PRECAUTIONS BOX 4

4 DOSAGE AND ADMINISTRATION..... 5

 4.1 Dosing Considerations 5

 4.2 Recommend Dose and Dosage Adjustment 5

 4.4 Administration 5

 4.5 Missed Dose 6

5 OVERDOSAGE..... 6

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING 8

7 WARNINGS AND PRECAUTIONS..... 8

 7.1 Special Populations 13

 7.1.1 Pregnant Women..... 13

 7.1.2 Breast-feeding..... 13

 7.1.3 Pediatrics..... 13

 7.1.4 Geriatrics..... 13

8 ADVERSE REACTIONS..... 14

 8.1 Adverse Reaction Overview 14

 8.2 Clinical Trial Adverse Reactions 14

 8.1.1 Clinical Trial Adverse Reactions – Pediatrics..... 15

	8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.....	15
	8.5 Post-Market Adverse Reactions.....	15
9	DRUG INTERACTIONS	16
	9.2 Drug Interactions Overview	16
	9.4 Drug-Drug Interactions	17
	9.5 Drug-Food Interactions.....	24
	9.6 Drug-Herb Interactions	24
10	CLINICAL PHARMACOLOGY	24
	10.1 Mechanism of Action	24
	10.2 Pharmacodynamics.....	24
	10.3 Pharmacokinetics.....	25
11	STORAGE, STABILITY AND DISPOSAL.....	27
12	SPECIAL HANDLING INSTRUCTIONS.....	27
	PART II: SCIENTIFIC INFORMATION	28
13	PHARMACEUTICAL INFORMATION	28
14	CLINICAL TRIALS	29
	14.1 Trial Design and Study Demographics	29
	14.2 Study Results.....	30
15	MICROBIOLOGY	30
	No microbiological information is required for this drug product.	30
16	NON-CLINICAL TOXICOLOGY	30
17	SUPPORTING PRODUCT MONOGRAPHS.....	34
	PATIENT MEDICATION INFORMATION	35

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

Seaford Nifedipine and Lidocaine Hydrochloride Cream is indicated in adults for the management of chronic primary anal fissure unresponsive to stool softeners and topical anesthetic agents.

1.1 Pediatrics

Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Geriatrics (> 65 years of age):

No data is available to Health Canada. Therefore, caution should be exercised in this population, and close monitoring is warranted. Evidence from experience suggests that the use of Lidocaine in the geriatric population is associated with differences in safety. (see 4. [DOSAGE AND ADMINISTRATION-Special Populations](#) and 7. [WARNINGS AND PRECAUTIONS-Special Populations](#)).

2 CONTRAINDICATIONS

Seaford Nifedipine and Lidocaine Hydrochloride Cream is contraindicated in:

- Patients with a known history of hypersensitivity to lidocaine and/or local anesthetics of the amide type or to other components of the cream including any non-medicinal ingredient. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).
- Patients with a known hypersensitivity to nifedipine or other dihydropyridines calcium antagonists, because of the theoretical risk of cross-reactivity.
- Pregnancy or women planning to become pregnant, and women breastfeeding.
- Patients with congenital or idiopathic methemoglobinemia, and patients with glucose-6-phosphate dehydrogenase deficiency which are more susceptible to drug-induced methemoglobinemia.
- Severe hypotension.
- Cardiac insufficiency.
- Cardiovascular shock.
- Recent myocardial infarction (in the previous month).
- Unstable angina.
- Concomitant use of diltiazem See [7. WARNINGS AND PRECAUTIONS](#) and [9. DRUG INTERACTIONS](#).
- Do not use in large quantities.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

SEAFORD NIFEDIPINE AND LIDOCAINE HYDROCHLORIDE CREAM can cause a rare, but serious, blood disorder called methemoglobinemia. It can appear up to two hours after you use SEAFORD NIFEDIPINE AND LIDOCAINE HYDROCHLORIDE CREAM. Stop using SEAFORD NIFEDIPINE AND LIDOCAINE HYDROCHLORIDE CREAM and talk to your healthcare professional immediately if you get

any of the following symptoms: weakness, confusion, headache, difficulty breathing, pale, grey or blue coloured skin.

See 8. ADVERSE REACTIONS

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

Geriatrics (> 65 years of age): Evidence from experience suggests that use in the geriatric population is associated with differences in safety. (see 4. 2 RECOMMEND DOSE AND DOSAGE ADJUSTMENT and 7. WARNINGS AND PRECAUTIONS-Geriatrics).

Assessment of blood pressure and heart rate should be considered before initiation of the treatment and during therapy, especially in those at higher risk of systemic effects. Discontinue use if a significant hypotension or change in heart rate is observed.

Pregnancy should be ruled out prior to treatment initiation (See 2. CONTRAINDICATIONS).

4.2 Recommend Dose and Dosage Adjustment

- Adults (18 to 65 years old):

30 g tube - One centimeter of topical Seaford Nifedipine and Lidocaine Hydrochloride Cream (equivalent to approximately 2.5-3 grams of cream) administered up to 1 cm inside the anus (and , if needed, around the anus (periannally)), twice daily for 3 weeks.

10 g tube (sample size) – 1.7 centimeter of topical Seaford Nifedipine and Lidocaine Hydrochloride Cream (equivalent to approximately 2.5-3 grams of cream) administered up to 1 cm inside the anus (and if needed, around the anus (periannally)), twice daily for 3 weeks.

One dose contains approximately 7.5 mg to 9 mg of nifedipine and 37.5 mg to 45 mg of lidocaine.

- Geriatrics (> 65 years of age):

Elderly patients should be closely monitored as they may be more sensitive to systemic effects due to increased blood levels of lidocaine following repeated doses.

- Pediatrics (<18 years of age):

Health Canada has not authorized an indication for pediatric use.

4.4 Administration

For application inside or around the anus.

Administer up to 1 cm inside the anus (and around the anus if needed): Lie down on the left side, remove the cap of the tube and fix the applicator (cannula). There are 10 markings on the side of the 30 g tube that are approximately 1 cm apart, and there are 3 markings on the side of the 10 g (sample) tube that are approximately 1.7 cm apart.

Squeeze out a small quantity of cream to lubricate the cannula and introduce it into the anus (up to 1 cm inside the anus). Release the cream until the next marking on the tube is reached (equivalent to approximately 2.5-3 grams of cream).

Remain on the left side for 3-5 minutes after application.

4.5 Missed Dose

If you forgot to take this medicine at the designated time, do not take a double dose. Wait until it is time for the next dose which should be taken at the usual time. Adhere to the treatment regimen as recommended by the doctor.

5 OVERDOSAGE

There have not been reported cases of systemic toxicity from the over dosage after the topical application of Seaford Nifedipine and Lidocaine Hydrochloride Cream. An intoxication after topical application of Seaford Nifedipine and Lidocaine Hydrochloride Cream should result in the systemic effects reported for Nifedipine and Lidocaine in general when administered by other routes of administration.

Acute systemic toxicity from local anesthetics is generally related to high plasma levels encountered during therapeutic use of local anesthetics and originates mainly in the central nervous and the cardiovascular systems. It should be kept in mind that clinically relevant pharmacodynamic drug interactions (i.e., toxic effects) may occur with lidocaine and other local anesthetics or structurally related drugs, and Class I and Class III antiarrhythmic drugs due to additive effects (see [9. DRUG INTERACTIONS](#)).

If overdose or accidental ingestion occurs, call a Poison Control Centre immediately.

Symptoms:

There are several well documented cases of oral nifedipine immediate-release overdose. The following symptoms are observed in cases of severe nifedipine intoxication: disturbance of consciousness to the point of coma, a drop in blood pressure, tachycardia/bradycardia, hyperglycemia, metabolic acidosis, hypoxia, cardiogenic shock with pulmonary oedema.

Central nervous system toxicity is a graded response with lidocaine, with symptoms and signs of escalating severity. The first symptoms are circumoral paresthesia, numbness of the tongue, light headedness, hyperacusis and tinnitus. Visual disturbance and muscular tremors are more serious and precede the onset of generalized convulsions. Unconsciousness and grand mal convulsions may follow, which may last from a few seconds to several minutes. Hypoxia and hypercarbia occur rapidly following convulsions due to the increased muscular activity, together with the interference with normal respiration. In severe cases apnea may occur. Acidosis, hyperkalaemia, hypocalcaemia and hypoxia increase and extend the toxic effects of local anesthetics.

Recovery is due to redistribution and metabolism of the local anesthetic drug. Recovery may be rapid unless large amounts of the drug have been administered.

Cardiovascular effects may be seen in cases with high systemic concentrations. Severe hypotension, bradycardia, arrhythmia and cardiovascular collapse may be the result in such cases.

Cardiovascular toxic effects are generally preceded by signs of toxicity in the central nervous system, unless the patient is receiving a general anesthetic or is heavily sedated with drugs such as a benzodiazepine or barbiturate.

Methemoglobinemia

Rare cases of methemoglobinemia have been reported with the use of topical lidocaine

Mild methemoglobinemia is characterized by tissue cyanosis, a bluish-grey or brownish discoloration of the skin, especially around the lips and nail beds, which is not reversed by breathing 100% oxygen. Clinical signs may also include pallor and marbleization.

Severe methemoglobinemia (MetHb concentrations above approximately 25%) is associated with signs of hypoxemia, i.e. dyspnea, tachycardia and depression of consciousness.

Drug-induced methemoglobinemia may occur with the use of drugs including but not limited to aminoamide, sulfonamides, acetanilid, aniline dyes, benzocaine, lidocaine, chloroquine, dapsone, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, paraaminosalicylic acid, phenacetin, phenobarbital, phenytoin, primaquine and quinine.

Acetaminophen has been shown to induce methemoglobin formation in vitro and in animals. In humans, methemoglobin formation is very rare at therapeutic doses and overdoses of acetaminophen.

Seaford Nifedipine and Lidocaine Hydrochloride Cream is contraindicated for patients with congenital or idiopathic methemoglobinemia. Patients with glucose-6-phosphate dehydrogenase deficiency are more susceptible to drug-induced methemoglobinemia (see [2. CONTRAINDICATIONS](#), [7. WARNINGS AND PRECAUTIONS](#)).

Treatment:

As far as treatment is concerned for nifedipine, elimination of the active substance and the restoration of stable cardiovascular conditions have priority. After oral ingestion, thorough gastric lavage is indicated, if necessary in combination with irrigation of the small intestine. Haemodialysis serves no purpose, as nifedipine is not dialysable, but plasmapheresis is advisable (high plasma protein binding, relatively low volume of distribution).

Clinically significant hypotension calls for active cardiovascular support including monitoring of cardiac and respiratory function including elevation of extremities and attention to circulating fluid volume and urine output.

Hypotension as a result of arterial vasodilation can also be treated with calcium (10 mL of 10% calcium gluconate solution administered slowly via intravenous route and repeated if necessary). As a result, the serum calcium can reach the upper normal range to slightly elevated levels. If an insufficient increase in blood pressure is achieved with calcium, vasoconstricting sympathomimetics such as dopamine or noradrenaline are additionally administered as a last resort only in patients without cardiac arrhythmia or ischemic heart disease and when other safer measures have failed. The dosage of these drugs is determined solely by the effect obtained. Additional liquid or volume must be administered with caution because of the danger of overloading the heart.

Bradycardia and/or bradyarrhythmias have been observed in some cases of nifedipine overdose. Appropriate clinical measures, according to the nature and severity of the symptoms, should be applied.

The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness after each local anesthetic administration. At the first sign of change, oxygen should be administered.

The first step in the management of systemic toxic reactions consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. This may prevent convulsions if they have not already occurred.

If convulsions occur, the objective of the treatment is to maintain ventilation and oxygenation and support circulation. Oxygen must be given and ventilation assisted if necessary (mask and bag or tracheal intubation). Should convulsions not stop spontaneously after 15-20 seconds, an anticonvulsant should be given iv to facilitate adequate ventilation and oxygenation. Thiopental sodium 1-3 mg/kg iv is the first choice. Alternatively diazepam 0.1mg/kg bw iv may be used, although its action will be slow. Prolonged convulsions may jeopardise the patient's ventilation and oxygenation. If so, injection of a muscle relaxant (e.g. succinylcholine 1mg/kg bw) will facilitate ventilation, and oxygenation can be controlled. Early endotracheal intubation is required when succinylcholine is used to control motor seizure activity.

If cardiovascular depression is evident (hypotension, bradycardia), ephedrine 5-10 mg i.v. should be given and may be repeated, if necessary, after 2-3 minutes.

Should circulatory arrest occur, immediate cardiopulmonary resuscitation should be instituted. Optimal oxygenation and ventilation and circulatory support as well as treatment of acidosis are of vital importance, since hypoxia and acidosis will increase the systemic toxicity of local anesthetics. Epinephrine (0.1-0.2 mg as intravenous or intracardial injections) should be given as soon as possible and repeated, if necessary.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Rectal	Cream / Nifedipine 0.3% w/w and Lidocaine Hydrochloride 1.5% w/w / Each gram of cream contains 3 mg of Nifedipine and 15 mg of Lidocaine HCl	Cetostearyl alcohol – Type A, Glycerol monostearate, Macrogol stearate, Paraffin, white soft, Propyl parahydroxybenzoate, Propylene glycol, Purified water, Sodium methyl parahydroxybenzoate, Triglycerides, medium-chain.

Packaging

Seaford Nifedipine and Lidocaine Hydrochloride Cream is available in:

- 30 g aluminum tube equipped with a cannula covered with a stopper in a cardboard box.
- 10 g aluminum tube equipped with a cannula covered with a stopper in a cardboard box.

As nifedipine is photosensitive, the primary packaging (tubes) are made of photoprotective material.

7 WARNINGS AND PRECAUTIONS

Please see 3. SERIOUS WARNINGS AND PRECAUTIONS BOX

General

Avoid contact with eyes; if this happens, rinse thoroughly with water.

Excessive dosage or short intervals between doses of Seaford Nifedipine and Lidocaine Hydrochloride Cream, can result in high plasma levels of nifedipine, lidocaine and/or their metabolites, which could lead to serious or life-threatening adverse effects. Patients should be instructed to strictly adhere to the recommended dosage, discontinue the treatment and to consult a health care practitioner if the following symptoms appear: weakness, confusion, headache, difficulty breathing and/or pale, grey or blue coloured skin as these may be signs of methemoglobinemia, a rare disorder, which may appear up to two (2) hours after use.

It is suggested to monitor arterial pressure at the beginning and periodically during the treatment.

In case of treatment failure of Seaford Nifedipine and Lidocaine Hydrochloride Cream (absence of improvement or worsening of the anal fissure or symptoms) the treatment must be stopped.

Seaford Nifedipine and Lidocaine Hydrochloride Cream should be used with caution in patients with sepsis and/or severely injured mucosa and phlogosis (inflammation) in the area to treat since this may cause excessive and/or rapid absorption of the active substances, and possibly increase the risk of systemic toxic effects.

The management of serious adverse reactions may require the use of resuscitative equipment, oxygen and other resuscitative drugs (see 5. OVERDOSAGE).

KEEP THIS MEDICINE OUT OF THE REACH AND SIGHT OF CHILDREN.

Carcinogenesis and Mutagenesis

Genotoxicity tests with lidocaine or nifedipine showed no evidence of mutagenic potential.

A metabolite of lidocaine, 2,6-xylidine, showed weak evidence of activity in some genotoxicity tests. See 16. NON-CLINICAL TOXICOLOGY for more information on carcinogenicity of 2,6-xylidine.

Cardiovascular

• Nifedipine

Seaford Nifedipine and Lidocaine Hydrochloride Cream is contraindicated in patient with cardiac insufficiency, severe hypotension, recent myocardial infarction (in the previous month), unstable angina, or cardiovascular shock. It is also contraindicated for concomitant use with diltiazem. (See 2. CONTRAINDICATIONS).

The use of Seaford Nifedipine and Lidocaine Hydrochloride Cream in patients being treated with beta-adrenergic blockers or antihypertensive drugs should be supervised by the physician. Caution should be exercised due to increased risks of severe hypotension, exacerbation of angina, or congestive heart failure. See 9.4 Drug-Drug Interactions.

Excessive Hypotension in Patients with Angina

Since oral nifedipine lowers peripheral vascular resistance and blood pressure, nifedipine should be used cautiously in patients with angina who are prone to develop hypotension and those with a history of cerebrovascular insufficiency.

Occasionally, excessive and poorly tolerated hypotension, and syncope have been reported (see 8. ADVERSE REACTIONS), usually during initial titration or at the time of subsequent upward dosage adjustment, and may be more likely in patients on concomitant beta blockers. If excessive hypotension occurs, the drug should be discontinued (see 2. CONTRAINDICATIONS).

Severe hypotension and/or increased fluid volume requirements have been reported in patients receiving oral nifedipine, with a beta blocker, who underwent coronary artery bypass surgery using high dose fentanyl anesthesia. The interaction with high dose fentanyl appears to be due to the combination of oral nifedipine and a beta blocker, but the possibility that it may occur with oral nifedipine alone, with low doses of fentanyl in other surgical procedures, or with other narcotic analgesics cannot be ruled out. When surgery using high dose fentanyl anesthesia is contemplated, the physician should be aware of these potential problems, and if the patient's condition permits, sufficient time (at least 36 hours) should be allowed for nifedipine to be washed out of the body prior to surgery.

Increased Angina and/or Myocardial Infarction

SEAFORD Nifedipine and Lidocaine Hydrochloride Cream is contraindicated in patients with recent myocardial infarction (in the previous month). Rarely, patients, particularly those who have severe obstructive coronary artery disease have developed increased frequency, duration and/or severity of angina or acute myocardial infarction on starting oral nifedipine or at the time of dosage increase. Nifedipine should not be used before the patient has stabilized. Nifedipine may increase the risk of reinfarction and worsen survival in patients treated early after myocardial infarction.

SEAFORD Nifedipine and Lidocaine Hydrochloride Cream is contraindicated in patients with unstable angina, due to increased risk of myocardial infarction and recurrent ischemia.

Beta-blocker Withdrawal

Patients with angina recently withdrawn from beta-blockers may develop a withdrawal syndrome with increased angina, at the initiation of treatment with nifedipine. It is important to taper beta-blockers if possible, rather than stopping them abruptly before starting nifedipine.

Patients with Heart Failure

SEAFORD Nifedipine and Lidocaine Hydrochloride Cream is contraindicated in patients with cardiac insufficiency. Severe hypotension and lowering of cardiac output following administration of oral nifedipine have been reported in patients with severe heart failure. Rarely, patients receiving a beta blockers developed heart failure after beginning nifedipine therapy.

Caution should be exercised in patients with severe aortic stenosis, as nifedipine may produce heart failure if the end-diastolic pressure is raised.

Hypotension/Heart Rate

SEAFORD Nifedipine and Lidocaine Hydrochloride Cream is contraindicated in patients with severe hypotension. Because nifedipine is an arterial and arteriolar vasodilator, hypotension, and a compensatory increase in heart rate may occur. Thus, blood pressure and heart rate should be monitored carefully during nifedipine therapy, especially for patients who are prone to develop hypotension, those with a history of cerebrovascular insufficiency, and those who are taking medications that are known to lower blood pressure.

Peripheral Edema

Mild to moderate peripheral edema (primarily in the lower extremities), typically associated with arterial vasodilation and not due to left ventricular dysfunction, has been reported in patients treated with oral nifedipine. With patients whose angina or hypertension is complicated by congestive heart failure, care should be taken to differentiate this peripheral edema from the effects of increasing left ventricular dysfunction.

• Lidocaine

Lidocaine should be used with caution in patients with bradycardia or impaired cardiovascular function since they may be less able to compensate for functional changes associated with the prolongation of A-V conduction produced by amide-type local anesthetics. Lidocaine should be used with caution in patients in severe shock. Patients treated with antiarrhythmic drugs (e.g., amiodarone, mexiletine) should be monitored, since cardiac effects of these drugs and lidocaine may be additive. [See 9. DRUG INTERACTIONS.](#)

Patients with partial or complete heart block require special attention since local anesthetics may depress myocardial conduction.

Driving and Operating Machinery

Due caution should be exercised when driving or operating a vehicle or potentially dangerous machinery.

Endocrine and Metabolism

The drug should be used with caution in diabetic patients.

Hepatic/Biliary/Pancreatic

Seaford Nifedipine and Lidocaine Hydrochloride Cream should be used with caution in those with hepatic insufficiency. These patients should be monitored more closely for systemic toxic effects. [See 10. CLINICAL PHARMACOLOGY.](#)

Because amide-type local anesthetics such as lidocaine are metabolized by the liver, these drugs, especially repeated doses, should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at greater risk of developing toxic plasma concentrations.

Peri-Operative Considerations

Many drugs used during the conduct of anesthesia are considered potential triggering agents for familial malignant hyperthermia. It has been shown that the use of amide local anesthetics in malignant hyperthermia patients is safe. However, there is no guarantee that neural blockade will prevent the development of malignant hyperthermia during surgery. It is also difficult to predict the need for supplemental general anesthesia. Therefore, a standard protocol for the management of malignant hyperthermia should be available.

Renal

Seaford Nifedipine and Lidocaine Hydrochloride Cream should be used with caution in patients with renal insufficiency.

Lidocaine is metabolized primarily by the liver to monoethylglycinexylidide (MEGX, which has some CNS activity), and then further to metabolites glycinexylidide (GX) and 2,6-dimethylaniline. Only a small fraction (2%) of lidocaine is excreted unchanged in the urine. The pharmacokinetics of lidocaine and its main metabolite were not altered significantly in haemodialysis patients (n=4) who received an intravenous dose of lidocaine. Therefore, renal impairment is not expected to significantly affect the

pharmacokinetics of lidocaine when Seaford Nifedipine and Lidocaine Hydrochloride Cream is used for short treatment durations, according to dosage instructions.

Caution is recommended when lidocaine is used in patients with severely impaired renal function because lidocaine and/or its metabolites may accumulate during treatment and may lead to toxic adverse effects.

For more complete information regarding Warnings and Precautions, please consult relevant Product Monograph ([See 17. SUPPORTING PRODUCT MONOGRAPHS](#)).

Reproductive Health: Female and Male Potential

Seaford Nifedipine and Lidocaine Hydrochloride Cream is contraindicated in pregnant women, and women who plan to become pregnant. [See 2. CONTRAINDICATIONS and 7.1.1. SPECIAL POPULATIONS Pregnant Women](#)

- **Fertility**

In some cases of in vitro fertilization, nifedipine has been associated with reversible spermatozoal biochemical changes. In vitro studies have shown that nifedipine may inhibit expression of mannose-ligand receptors, thus preventing the spermatozoa from attaching to the zona pellucida and impairing sperm function. In those men who are repeatedly unsuccessful in fathering a child by in vitro fertilization, and where no other explanation could be found, nifedipine should be considered as a possible cause.

An *in vivo* study on rats showed that nifedipine is associated with detrimental and reversible effects on sperm function. No changes in fertility due to lidocaine have been reported. [See 16. NON-CLINICAL TOXICOLOGY](#)

- **Teratogenic Risk**

Seaford Nifedipine and Lidocaine Hydrochloride Cream is contraindicated during pregnancy and breast feeding ([See 2. CONTRAINDICATIONS, 7.1.1. Pregnant Women; 7.1.2. Breast-feeding](#))

Teratogenic effects (increased number of fetal mortalities and resorptions) in mice, rats, and rabbits were reported with nifedipine. [See 16. NON-CLINICAL TOXICOLOGY](#)

Studies with lidocaine have not shown significant risks to the fetus. [See 16. NON-CLINICAL TOXICOLOGY](#).

Sensitivity/Resistance

Seaford Nifedipine and Lidocaine Hydrochloride Cream is contraindicated in patients with known hypersensitivities to lidocaine and/or local anesthetics of the amide type or to other components of the cream including any non-medicinal ingredient.

Seaford Nifedipine and Lidocaine Hydrochloride Cream is also contraindicated in patients with a hypersensitivity to nifedipine or to other dihydropyridines calcium antagonists, because of the theoretical risk of cross-reactivity.

Seaford Nifedipine and Lidocaine Hydrochloride Cream contains sodium methyl parahydroxybenzoate and propyl parahydroxybenzoate which can cause allergic reactions, including delayed allergic reactions.

Lidocaine should be used with caution in persons with known drug sensitivities. Patients allergic

to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine.

Skin

The topical administration of the drug for prolonged periods may cause sensitivity reactions, local hyperemia and bleeding that resolve when the treatment is discontinued.

Seaford Nifedipine and Lidocaine Hydrochloride Cream for rectal use should be used with caution in patients with sepsis and/or severely injured mucosa and phlogosis (inflammation) in the area to treat since this may cause excessive and/or rapid absorption of the active substances, and possible increase risk in systemic adverse effects.

Seaford Nifedipine and Lidocaine Hydrochloride Cream contains propylene glycol and cetostearyl alcohol which can cause local skin reactions (e.g. contact dermatitis).

7.1 Special Populations

7.1.1 Pregnant Women

Seaford Nifedipine and Lidocaine Hydrochloride Cream is contraindicated during pregnancy ([See 2. CONTRAINDICATIONS](#))

Nifedipine and Lidocaine cross the placental barrier.

Teratogenic effects (increased number of fetal mortalities and resorptions) in mice, rats, and rabbits were reported with nifedipine. [See 16. NON-CLINICAL TOXICOLOGY](#)

Animal studies with lidocaine have not shown significant risks to the fetus. [See 16. NON-CLINICAL TOXICOLOGY](#).

7.1.2 Breast-feeding

Seaford Nifedipine and Lidocaine Hydrochloride Cream is contraindicated during breast-feeding ([See 2. CONTRAINDICATIONS](#))

Nifedipine and Lidocaine are excreted in breast milk.

The metabolites of lidocaine are also excreted in breast milk.

7.1.3 Pediatrics

No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

7.1.4 Geriatrics

Geriatrics (> 65 years of age): Evidence from experience suggests that use in the geriatric population is associated with differences in safety. Elderly patients may be more sensitive to systemic effects due to increased blood levels of lidocaine following repeated doses. Therefore, caution should be exercised in this population, and close monitoring is warranted.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Lidocaine

Adverse experiences following the administration of lidocaine are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by overdosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature.

Nifedipine

Because drugs containing nifedipine have a vasodilating effect, hypotension, tachycardia, or syncope may occur.

Safety data supporting the use of Seaford Nifedipine and Lidocaine Hydrochloride Cream have been collected from clinical studies conducted on patients with anal fissure and patients with damaged anorectal mucosa. The most frequently reported adverse reactions from subjects receiving Seaford Nifedipine and Lidocaine Hydrochloride Cream were local hyperemia / erythema reported in 2% to 4% of patients, headache, sphincter pain, hypertension, fecal incontinence, nausea, vomiting, proctorrhagia upon defecation

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

In study P001/98, in 55 patients with chronic anal fissures treated with Seaford Nifedipine and Lidocaine Hydrochloride Cream twice daily for three weeks, the average diastolic blood pressure was not significantly different from pretreatment levels.

In study Antro-0206, conducted in 135 patients with damaged anorectal mucosa (following anorectal surgery) treated twice daily with Seaford Nifedipine and Lidocaine Hydrochloride Cream for two weeks, one case of headache led to drug discontinuation. No deaths or serious adverse reactions related to Seaford Nifedipine and Lidocaine Hydrochloride Cream were reported. The following table includes adverse reactions more frequently reported with Seaford Nifedipine and Lidocaine Hydrochloride Cream as compared to a galenic Lidocaine ointment.

Table 2 - Incidence (%) of Adverse reactions (≥1.5% with Seaford Nifedipine and Lidocaine Hydrochloride Cream) in patients following anorectal surgery

System Organ Class	Seaford Nifedipine and Lidocaine Hydrochloride Cream N=135(%)	1.5% Lidocaine Ointment* N=135 (%)
Ear and labyrinth disorders		
Vertigo †	8 (5.9%)	3 (2.2%)
Gastrointestinal disorders		
Nausea/vomiting	11 (8.1%)	6 (4.4%)
Anal burning/pruritus	8 (5.9%)	2 (1.5%)
Proctalgia/Anal spasm	2 (1.5%)	1 (0.7%)
Anal inflammation/Anal prolapse	3 (2.2%)	2 (1.5%)
Nervous system disorders		
Headache	12(8.9%)	11(8.1%)
Renal and urinary disorders		
Urinary retention †	5 (3.7%)	0
Micturition disorder/dysuria †	2 (1.5%)	0

*: galenic formulation of 1.5% lidocaine cream.

†: causal relationship to the drug was not established

8.1.1 Clinical Trial Adverse Reactions – Pediatrics

No safety data is available in the pediatric population.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Clinical Trial Findings

No clinical laboratory evaluations have been conducted in the safety studies.

Vital Signs, Physical Findings, and Other Observations Related to Safety

Only slight but non-significant variations of blood pressure and heart rate were reported.

8.5 Post-Market Adverse Reactions

Hypersensitivity reactions due to the drug such as Urticaria and edema has been reported.

The following are adverse reactions mostly from published studies.

Table 3 Adverse Drug Reactions based on published studies

System organ class	Frequency	ADRs
Vascular disorders	Common	Mild, localised hyperaemia
	Uncommon	Hypertension; Hot flush
	Not known	Hypotension
Cardiac disorders	Not known	Tachycardia
Nervous system disorders	Common	Syncope
Immune system disorders	Not known	Angio-oedema, urticaria, laryngeal oedema, face oedema
Gastrointestinal disorders	Uncommon	Proctalgia, anal incontinence, hematochezia
Injury, poisoning and Procedural complications	Uncommon	Wound oedema

Very common ($\geq 10\%$), common ($\geq 1\%$ and $< 10\%$), uncommon ($\geq 0.1\%$ and $< 1\%$), rare ($\geq 0.01\%$ and $< 0.1\%$), very rare ($< 0.01\%$) including isolated reports.

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

Treatment with Seaford Nifedipine and Lidocaine Hydrochloride Cream may increase the effect of antihypertensive drugs due to the presence of nifedipine.

Nifedipine

Nifedipine undergo biotransformation by the cytochrome P450 system, mainly via the CYP3A4 isoenzyme. Coadministration of nifedipine with other drugs which follow the same route of biotransformation may result in altered bioavailability ([see 9.4 DRUG-DRUG INTERACTIONS](#)).

Lidocaine

Cimetidine may increase the plasmatic levels of Nifedipine and Lidocaine. The contemporaneous administration of Seaford Nifedipine and Lidocaine Hydrochloride Cream for rectal use in patients in treatment with digoxin may increase the plasmatic levels of digoxin.

Lidocaine is mainly metabolized in the liver by CYP1A2 and CYP3A4 to its two major metabolites, monoethylglycinexylidene (MEGX) and glycinexylidene (GX), both of which are pharmacologically active. Lidocaine has a high hepatic extraction ratio. Only a small fraction (2%) of lidocaine is excreted unchanged in the urine. The hepatic clearance of lidocaine is expected to depend largely on blood flow.

Strong inhibitors of CYP1A2, such as fluvoxamine, given concomitantly with lidocaine, can lead to an increased lidocaine plasma concentration. Therefore, prolonged administration of lidocaine should be avoided in patients treated with strong inhibitors of CYP1A2, such as fluvoxamine.

When co-administered with intravenous lidocaine, two strong inhibitors of CYP3A4, erythromycin and itraconazole, have each been shown to have a modest effect on the pharmacokinetics of intravenous lidocaine. Other drugs such as propranolol and cimetidine have been reported to reduce intravenous lidocaine clearance, probably through effects on hepatic blood flow and/or metabolism.

When lidocaine is used topically, plasma concentrations are of importance for safety reasons (see 7. WARNINGS AND PRECAUTIONS, General; 8. ADVERSE REACTIONS).

Clinically relevant pharmacodynamic drug interactions may occur with lidocaine and other local anesthetics or structurally related drugs, and Class I and Class III antiarrhythmic drugs due to additive effects.

9.3 Drug-Behavioural Interactions

Interactions with behaviour have not been established.

9.4 Drug-Drug Interactions

Nifedipine

Treatment with Seaford Nifedipine and Lidocaine Hydrochloride Cream may increase the effect of antihypertensive drugs on blood pressure due to the presence of nifedipine.

When nifedipine is administered simultaneously with beta-receptor blockers, the patient should be carefully monitored, since deterioration of heart failure have been reported in isolated cases.

- Digoxin : The simultaneous administration of nifedipine and digoxin may lead to reduced digoxin clearance and, hence, an increase in the plasma digoxin level. The patient should therefore be subjected to precautionary checks for symptoms of digoxin overdosage and, if necessary, the glycoside dose should be reduced.
- Cytochrome P-450 (CYP3A4) Enzyme Substrates : Drugs known to be biotransformed via cytochrome P450 include: benzodiazepines, cisapride, tacrolimus, imipramine propafenone, terfenadine and warfarin (see Table 4).
- Cytochrome P-450 (CYP3A4) Enzyme Inhibitors : Drugs known to be inhibitors of the cytochrome P450 system include: azole antifungals (ketoconazole, itraconazole, fluconazole), cimetidine, clarithromycin, cyclosporine, erythromycin, fluoxetine, HIV protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir), nefazodone, and quinidine. Enzyme inhibitors of the cytochrome P450 3A4 system have been shown to cause an increase in nifedipine plasma concentrations (see Table 4).
- Cytochrome P-450 (CYP3A4) Enzyme Inducers : Enzyme inducers of the cytochrome P450 3A4 system have been shown to cause a decrease in plasma concentrations of nifedipine, e.g. Hypericum perforatum (Saint John’s Wort) (see 9.6. Drug- Herb Interactions), phenobarbital, phenytoin, and rifampicin (see Table 4).

Table 4 - Established or Potential Drug-drug Interactions for Nifedipine

Proper Name		Ref	Effect	Clinical Comment
CYP3A4 Substrates	CYP3A4 substrates (eg, cisapride, tacrolimus, benzodiazepines, imipramine, propafenone, terfenadine, warfarin)	N/A	Enzyme substrates of the cytochrome P450 3A4 (CYP3A4), when coadministered with nifedipine, may act like CYP3A4 inhibitors and cause an increase in nifedipine plasma concentrations.	Dose adjustment and monitoring may be required.

	Cisapride	CT	Simultaneous administration of cisapride may lead to increased plasma concentrations of nifedipine.	Blood pressure should be monitored and, if necessary, a reduction of the nifedipine dose considered.
	Tacrolimus	C	The dose of tacrolimus administered simultaneously with nifedipine may be reduced in individual cases.	Tacrolimus plasma concentrations should be monitored (and reduced if necessary).
CYP3A4 Inhibitors	CYP3A4 inhibitors: (eg, azole antifungals (ketoconazole, itraconazole, fluconazole), cimetidine, cyclosporine, erythromycin, fluoxetine, HIV protease inhibitors , nefazodone, quinidine)	N/A	Enzyme inhibitors of CYP3A4 have been shown to cause an increase in nifedipine plasma concentrations, and therefore an increased hypotensive effect of nifedipine.	Avoid concomitant administration of nifedipine with strong CYP3A4 inhibitors. Dose adjustment and monitoring may be required.
	Azole anti-mycotics (eg, ketoconazole)	T	Drugs of this class are known to inhibit the cytochrome P450 3A4 system.	When administered orally together with nifedipine, a substantial increase in systemic bioavailability of nifedipine due to a decreased first pass metabolism cannot be excluded.
	Cimetidine and Ranitidine	CT	Pharmacokinetic studies have shown that concurrent administration of cimetidine or ranitidine with nifedipine results in significant increases in nifedipine plasma levels (ca. 80% with cimetidine and 70% with ranitidine).	Patients receiving either of these drugs concomitantly with nifedipine should be monitored carefully for the possible exacerbation of effects of nifedipine, such as hypotension. Adjustment of nifedipine dosage may be necessary.
	Diltiazem	CT	Diltiazem decreases the clearance of nifedipine.	The combination of both drugs should be administered with caution, and a reduction of the nifedipine dose may be considered.

Erythromycin	T	No interaction studies have been carried out between nifedipine and macrolide antibiotics. Certain macrolide antibiotics are known to inhibit the cytochrome P450 3A4 mediated metabolism of other drugs.	The potential for an increase of nifedipine plasma concentrations upon co-administration of both drugs cannot be excluded
Clarithromycin	T	Increased incidence of acute kidney injury requiring hospitalization, which may have been caused by increased hypotensive reactions.	Concomitant use should be avoided.
Fluoxetine	T	A clinical study investigating the potential of a drug interaction between nifedipine and fluoxetine has not yet been performed. Fluoxetine has been shown to inhibit in vitro the cytochrome P450 3A4 mediated metabolism of nifedipine.	Therefore an increase of nifedipine plasma concentrations upon co-administration of both drugs cannot be excluded
HIV protease inhibitors	T	A clinical study investigating the potential of a drug interaction between nifedipine and certain anti-HIV protease inhibitors has not yet been performed. Drugs of this class are known to inhibit the cytochrome P450 3A4 system. In addition, drugs of this class have been shown to inhibit in vitro the cytochrome P450 3A4 mediated metabolism of nifedipine.	When administered together with nifedipine, a substantial increase in plasma concentrations of nifedipine due to a decreased first pass metabolism and a decreased elimination cannot be excluded
Nefazodone	T	A clinical study investigating the potential of a drug interaction between nifedipine and nefazodone has not yet been performed. Nefazodone is known to inhibit the cytochrome P450 3A4 mediated metabolism of other drugs.	Therefore an increase of nifedipine plasma concentrations upon co-administration of both drugs cannot be excluded

	Quinidine	CT	Nifedipine may reduce quinidine level by 50%, an enhanced response to nifedipine may also occur. Quinidine may induce elevated nifedipine concentrations and reduced response to quinidine. Some patients have experienced elevated quinidine levels when nifedipine was discontinued.	Patients receiving concomitant therapy of nifedipine and quinidine, or those who had their nifedipine discontinued while still receiving quinidine, should be closely monitored, including determination of quinidine plasma levels. Dosage adjustment should be considered.
	Quinupristin/ Dalfopristin	CT	Simultaneous administration of quinupristin/dalfopristin and nifedipine may lead to increased plasma concentrations of nifedipine.	Upon coadministration of both drugs, blood pressure should be monitored and, if necessary, a reduction of the nifedipine dose should be considered
	Valproic Acid	T	Valproic acid increases the plasma concentrations of the structurally similar calcium channel blocker nimodipine due to enzyme inhibition, therefore, an increase in nifedipine plasma concentrations and efficacy cannot be excluded.	Caution and careful monitoring of patients on concomitant therapy is recommended.
CYP3A4 Inducers	CYP3A4 Inducers (eg, Phenytoin, Carbamazepine , Phenobarbital, rifampicin)	N/A	May increase the first pass effect or the clearance of nifedipine, which may reduce the bioavailability and efficacy of nifedipine.	A pharmacodynamic interaction exists, inhibiting effective use of quinidine. Need for careful clinical and laboratory monitoring of patients receiving both classes of medication.
Non-CYP3A4 Interactions	Coumarin Anticoagulants	C	Rare reports described increased prothrombin time in patients taking coumarin anticoagulants and nifedipine. However, the relationship to nifedipine therapy is uncertain.	Caution and careful monitoring is recommended.

Beta Adrenergic Blocking Agents	CT	Concomitant administration of nifedipine and beta blocking agents is usually well tolerated, but occasional literature reports suggest that it may increase the likelihood of congestive heart failure, severe hypotension, or exacerbation of angina.	Caution and careful monitoring is recommended (see 1. INDICATIONS and 7. WARNINGS AND PRECAUTIONS, Cardiovascular).
Digoxin	CT	Administration of nifedipine with digoxin may reduce digoxin clearance which increases plasma digoxin level.	It is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible “underdosing” or “overdosing” with digitalis.
Long-acting Nitrates	T	Nifedipine may be safely coadministered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.	No dosage adjustment necessary.
Theophylline	C / CT	Co-administration of nifedipine may cause alterations in theophylline levels.	Monitoring of theophylline serum levels should be considered.

C=Case Study; CT=Clinical Trial; T=Theoretical; N/A = Not Applicable

Lidocaine

- Local anesthetics and agents structurally related to amide-type local anesthetics Lidocaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics (e.g. antiarrhythmics such as mexiletine), since the toxic effects are additive.

- Antiarrhythmic Drugs:

Class I Antiarrhythmic drugs

Class I antiarrhythmic drugs (such as mexiletine) should be used with caution since toxic effects are additive and potentially synergistic.

- Class III Antiarrhythmic drugs

Caution is advised when using Class III antiarrhythmic drugs concomitantly with lidocaine due to potential pharmacodynamic or pharmacokinetic interactions with lidocaine, or both. A drug interaction study has shown that the plasma concentration of lidocaine may be increased following administration of a therapeutic dose of intravenous lidocaine to patients treated with amiodarone (n=6). Case reports

have described toxicity in patients treated concomitantly with lidocaine and amiodarone. Patients treated with Class III antiarrhythmic drugs (e.g. amiodarone) should be kept under close surveillance and ECG monitoring should be considered, since cardiac effects of these drugs and lidocaine may be additive.

- Strong Inhibitors of CYP1A2 and CYP3A4

Cytochrome CYP1A2 and CYP3A4 are involved in the formation of the pharmacologically active lidocaine metabolite MEGX.

Fluvoxamine: Strong inhibitors of CYP1A2, such as fluvoxamine, given during prolonged administration of lidocaine to areas with a high extent of systemic absorption (e.g., mucous membranes) can cause a metabolic interaction leading to an increased lidocaine plasma concentration. The plasma clearance of a single intravenous dose of lidocaine was reduced by 41 to 60% during co-administration of fluvoxamine, a selective and potent CYP1A2 inhibitor, to healthy volunteers.

Erythromycin and Itraconazole: Erythromycin and itraconazole, which are strong inhibitors of CYP3A4, have been shown to reduce clearance of lidocaine by 9 to 18%, following a single intravenous dose of lidocaine to healthy volunteers.

During combined co-administration with fluvoxamine and erythromycin the plasma clearance of lidocaine was reduced by 53%.

- β -blockers and cimetidine

Following a single intravenous dose of lidocaine, administered to healthy volunteers, the clearance of lidocaine has been reported to be reduced up to 47% when co-administered with propranolol and up to 30% when co-administered with cimetidine. Reduced clearance of lidocaine when co-administered with these drugs is probably due to reduced liver blood flow and/or inhibition of microsomal liver enzymes. The potential for clinically significant interactions with these drugs should be considered during long-term treatment with high doses of lidocaine.

- Methemoglobinemia

In patients treated concomitantly with 5% topical lidocaine and other methemoglobin inducing agents including but not limited to sulfonamides, acetanilid, aniline dyes, benzocaine, chloroquine, dapsone, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic acid, phenacetin, phenobarbital, phenytoin, primaquine and quinine, topical lidocaine may induce the formation of methemoglobin and result in overt clinical signs of methemoglobinemia (see 2. CONTRAINDICATIONS and 5. OVERDOSAGE).

Acetaminophen has been shown to induce methemoglobin formation in vitro and in animals. In humans, methemoglobin formation is very rare at therapeutic doses and overdoses of acetaminophen.

Table 5 - Established or Potential Drug-Drug Interactions

Proper/Common name	Source of Evidence	Effect	Clinical comment
Antihypertensive	T	May increase the effect of antihypertensive drugs	Caution is warranted and therapeutic concentration monitoring is recommended
Beta-receptor blockers	C	May led to deterioration of heart failure	Patients should be carefully monitored

Digoxine	T	May lead to reduced digoxin clearance and, hence, an increase in the plasma digoxin level	Patients should be subjected to precautionary checks for symptoms of digoxin overdosage and, if necessary, the glycoside dose should be reduced
Cimetidine equal or higher doses than 800 mg/day	T	May increase the plasmatic levels of nifedipine and lidocaine	Patients should be carefully monitored
Local anesthetics and agents structurally related to amide-type local anesthetics	T	Toxic effects are additive	Used with caution
<u>Class I Antiarrhythmic drugs</u>	T	Toxic effects are additive and potentially synergistic	Used with caution
Class III Antiarrhythmic drugs	T	Cardiac effects of these drugs and lidocaine may be additive	Patients should be carefully monitored
<i>Fluvoxamine</i>	T	Increased lidocaine plasma concentration	Patients should be carefully monitored
<i>Erythromycin and Itraconazole</i>	T	Reduce clearance of lidocaine	Patients should be carefully monitored
Methemoglobin inducing agents including but not limited to acetaminophen, sulfonamides, acetanilid, aniline dyes, benzocaine, chloroquine, dapson, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic acid, phenacetin, phenobarbital, phenytoin, primaquine and quinine	T	May induce the formation of methemoglobin and result in overt clinical signs of methemoglobinemia	Patients should be carefully monitored

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

9.5 Drug-Food Interactions

Nifedipine

Nifedipine is metabolized by the cytochrome P450 enzyme system, predominantly via CYP3A4, but also by CYP1A2 and CYP2A6 isoenzymes. Compounds found in grapefruit juice inhibit the cytochrome P450 system, especially CYP3A4. In a grapefruit-juice-nifedipine interaction study in healthy male volunteers, pharmacokinetics of nifedipine showed significant alteration. Following administration of a single oral dose of nifedipine 10 mg with 250 mL grapefruit juice, the mean value of nifedipine AUC increased by 34% and the t_{max} increased from 0.8 hours to 1.2 hours as compared to water.

Patients should avoid consuming grapefruit juice during treatment.

Lidocaine

Interactions with food have not been established regarding lidocaine.

9.6 Drug-Herb Interactions

Hypericum perforatum – Saint John's Wort is an inducer of CYP3A4 and has been shown to cause a decrease in plasma concentrations of nifedipine.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

The mechanism of action for Seaford Nifedipine and Lidocaine Hydrochloride Cream results from the combined effects of each active ingredient.

Nifedipine, is a dihydropyridine calcium ion influx inhibitor (calcium channel blocker or calcium ion antagonist) with vasodilatory action. When used locally, it has a relaxing action on the peripheral smooth musculature. The exact mechanism of action of nifedipine in the treatment of anal fissures is not fully understood, however, it may act by reducing the internal anal sphincter hypertonia, and possibly increasing the blood flow to the lesion area, which may help the healing processes.

Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Local anesthetics of the amide type are thought to act within the sodium channels of the nerve membrane.

10.2 Pharmacodynamics

Nifedipine

In vitro data using muscle strips showed that nifedipine can reduce the resting tone in the internal anal sphincter.

A clinical study of patients with chronic anal fissures suggested that after 21 days of treatment with Seaford Nifedipine and Lidocaine Rectal Cream twice daily, the mean anal resting pressure decreased by 11%, from a mean value ± standard deviation of 47.2 ± 14.6 to 42 ± 12.4 mmHg. Following a single dose of SEAFORD Nifedipine and Lidocaine Hydrochloride Cream, in patients with damaged anorectal

mucosa, the data suggested a tendency towards lower mean systolic and diastolic blood pressure and a slight decrease in mean heart rate (observed between 1 and 3 hours post-dose).

Lidocaine

Lidocaine, like other local anesthetics, may also have effects on excitable membranes in the brain and myocardium. If excessive amounts of drug reach systemic circulation rapidly, symptoms and signs of toxicity will appear, emanating from the central nervous and cardiovascular systems.

Central nervous system toxicity (see 5. OVERDOSAGE) usually precedes the cardiovascular effects since it occurs at lower plasma concentrations. Direct effects of local anesthetics on the heart include slow conduction, negative inotropism and eventually cardiac arrest.

10.3 Pharmacokinetics

A study showed that the application of Seaford Nifedipine and Lidocaine Hydrochloride Cream onto damaged anorectal mucosa induces some systemic absorption of nifedipine in few patients. However, lidocaine was quantifiable in all patients, but at levels below the threshold of central nervous system toxicity. Therefore, although not likely to elicit systemic adverse reactions, systemic absorption cannot be definitely ruled out it.

Absorption:

The rate and extent of absorption depends upon concentration and total dose administered, the specific site of application, skin and/or mucosa condition, and duration of exposure.

In general, the rate of absorption of local anesthetic agents, following topical application to wound surfaces and mucous membranes is high. A study with Seaford Nifedipine and Lidocaine Hydrochloride Cream used on damaged anorectal mucosa showed absorption of trace amounts of nifedipine and lidocaine in some of the patients.

Distribution:

Lidocaine has a total plasma clearance of 0.95 L/min and a volume of distribution at steady state of 91 L. Lidocaine readily crosses the placenta, and equilibrium in regard to free, unbound drug will be reached. Because the degree of plasma protein binding in the fetus is less than in the mother, the total plasma concentration will be greater in the mother, but the free concentrations will be the same. The plasma binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 µg of free base per mL, 60 to 80 percent of lidocaine is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.

Nifedipine is highly bound to human plasma proteins (range from 92 to 98%) and is concentration-dependent, with a relatively low volume of distribution. It is also known to be distributed into breast milk.

Metabolism:

Lidocaine is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. Only 2% of lidocaine is excreted unchanged. Most of it is metabolized first to monoethylglycinexylidide (MEGX) and then to glycinexylidide (GX) and 2,6-dimethylaniline. Up to 70% appears in the urine as 4-hydroxy-2,6-dimethylaniline.

Nifedipine is extensively metabolised in the liver (to three highly water-soluble and pharmacologically inactive metabolites) by the cytochrome P-450 microsomal enzyme system, predominantly by CYP3A but also by CYP1A2 and CYP2A6 isozymes.

Compounds found in grapefruit juice inhibit the cytochrome P450 system, especially CYP3A4, resulting in significant changes in pharmacokinetics of nifedipine when ingested concomitantly (increase in nifedipine AUC (+34%) and T_{max} (from 0.8 hours to 1.2 hours) (see 9. DRUG INTERACTIONS: 9.5. Drug-Food Interactions).

Nifedipine, when administered in the lower part of the rectum, can bypass the liver, and therefore, may avoid, in a large part, the hepatic first pass metabolism.

Elimination

Lidocaine has an elimination half-life of 1.6 h and an estimated hepatic extraction ratio of 0.65. The clearance of lidocaine is almost entirely due to liver metabolism, and depends both on liver blood flow and the activity of metabolizing enzymes. The elimination half-life of lidocaine following an intravenous bolus injection is typically 1.5 to 2.0 hours. The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites.

Nifedipine is extensively metabolized to highly water-soluble, inactive metabolites accounting for 60 to 80% of the dose excreted in the urine. The remainder is excreted in the feces in metabolized form, most likely as a result of biliary excretion. The main metabolite (95%) is the hydroxycarboxylic acid derivative; the remaining 5% is the corresponding lactone. Only traces (<0.1%) of unchanged nifedipine can be detected in the urine.

The elimination half-life of nifedipine is dependent upon the dosage form in which it is administered. This data is not available for Seaford Nifedipine and Lidocaine Rectal Cream administered rectally.

Special Populations and Conditions

The following precautions should be noted:

- The cream should be used with caution in patients with severely injured mucosa and phlogosis (inflammation) in the area to treat since this may cause excessive absorption of the active substances.
- The drug should be used with caution in diabetic patients or in those with hepatic and/or renal insufficiency.

Lidocaine

Acidosis increases the systemic toxicity of lidocaine while the use of CNS depressants may increase the levels of lidocaine required to produce overt CNS effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6.0 µg free base per mL. Debilitated, acutely ill patients, and patients with sepsis, may be more sensitive to systemic effects due to increased blood levels of lidocaine following repeated doses.

Renal impairment does not affect the clearance of lidocaine but accumulation of its active metabolites can occur.

Nifedipine

- **Hepatic Insufficiency**

A clinically significant alteration in the pharmacokinetics of nifedipine (prolonged elimination half-life and decreased total clearance) was noted in patients with hepatic cirrhosis leading to a considerable risk of accumulation. Protein binding may be greatly reduced in patients with hepatic impairment.

- **Sex**

The clearance of nifedipine may be slower in men compared to women after oral administration of nifedipine.

- **Ethnic Origin**

Higher systemic exposure of nifedipine and lower first pass metabolism in South Asians compared with Caucasians may occur following administration of oral nifedipine. Clearance of nifedipine may be slower in African American subjects compared with white subjects [\[2.7.2.2.2\]](#)

11 STORAGE, STABILITY AND DISPOSAL

Store at 15°C to 25°C.

Do not freeze.

Protect from light.

Keep out of reach and sight of children.

12 SPECIAL HANDLING INSTRUCTIONS

None

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance


Nifedipine:

Proper name: Nifedipine

Chemical name: 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridine-dicarboxylic acid dimethyl ester

Molecular formula and molecular mass: $C_{17}H_{18}N_2O_6$; 346.3

Structural formula:



Physicochemical properties: Nifedipine is a pyridine dicarboxylic acid dimethylester. It is a fine yellowish powder, practically insoluble in water freely soluble in acetone and sparingly soluble in ethanol. It is light-sensitive, and when exposed, is converted to a pharmacologically inactive pyridine derivative via an intramolecular redox process.


Lidocaine:

Proper name: Lidocaine Hydrochloride

Chemical name: 2-Diethylamino-N-(2,6-dimethylphenyl)-acetamide monohydrochloride monohydrate

Molecular formula and molecular mass: $C_{14}H_{22}N_2O \cdot HCl \cdot H_2O$; 288.8

Structural formula:



Physicochemical properties: White crystalline powder. Very soluble in water, freely soluble in alcohol. Melting range between 74 and 79°C. pH of 4.0 to 5.5 (0.5% solution in H₂O).

14 CLINICAL TRIALS

14.1 Trial by indication

Chronic Anal Fissures

Table 6: Trial Design and Study Demographics

Study #	Study Design	Dosage, route of administration and duration	No. Of Subjects	Mean age (range)	Sex M/F
P001/98	Prospective, randomized double-blind, active control, phase 3	SEAFORD NIFEDIPINE AND LIDOCAINE HYDROCHLORIDE CREAM; 3 g ointment; anal and peri-anal; twice daily for 3 weeks Control group: Hydrocortisone acetate 1%, Lidocaine 1.5%; 3 g; ointment; twice daily for 3 weeks	110 adult patients	Treatment group: 43.2 yrs (17-77) Control group: 45.5 yrs (20-71)	Treatment group: M: 43 (78%)/ F: 12 (22%); Control group: M: 36 (66%)/ F: 19(34%);

The pivotal P001/98 study was a randomized double-blind parallel controlled study conducted in 110 patients aged 18 years and older with chronic anal fissure. Patients were mainly males (72%) with no underlying pathology or concomitant local condition, such as neoplasms, fistulas, perianal abscess, or prolapse. Patients had a history of anal pain for at least two months despite treatment with stool softeners and topical anesthetic agents.

Patients were randomized into two treatment groups to receive either Seaford Nifedipine and Lidocaine Hydrochloride Cream or a control ointment (hydrocortisone acetate 1% with lidocaine 1.5%).

The participants administered 3 g of ointment twice daily for 3 weeks and lay on the left side on the bed for three to five minutes.

The primary efficacy endpoint on day 21 of treatment was healing of the fissure with epithelialization or scarring.

14.2 Study Results

After 21 days of treatment, the proportion of patients with healing of anal fissure was significantly larger in the group treated with Seaford Nifedipine and Lidocaine Hydrochloride Cream, compared to the group treated with the control. See Table 7 below.

Table 7 - Results for primary efficacy endpoint: Healing of Anal Fissure (Study P001/98)

	Seaford Nifedipine and Lidocaine Hydrochloride Cream 3 g twice daily	Control ointment (hydrocortisone acetate 1% with lidocaine 1.5%) 3 g twice daily
Healing complete or almost complete*	52 (94.5%) †	9 (16.4%)
Little or no change	3 (5.5%)	46 (83.6%)

* Fissure healed with scarring/epithelialization, or Ulcerative lesion in the process of complete scarring/epithelialization.

†: Difference in healing rates vs. control (94.5% vs 16.4%) was 78.1%, and p-value <0.001.

Relief of anal pain tended to be more frequently reported in the Seaford Nifedipine and Lidocaine Hydrochloride Cream group (87.3%) as compared to the control group (10.9%).

Resting anal pressure was possibly lower after treatment in the Seaford Nifedipine and Lidocaine Hydrochloride Cream group compared to the control group.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology:

Acute Toxicity Studies

Nifedipine and Lidocaine combination administered rectally In rats, reversible dysfunctions of motor activity and mechanical reactions were observed following a single rectal dose of 2 g/kg of nifedipine and lidocaine (0.3% and 1.5% w/w) rectal cream. No drug-related mortality was observed.

When rats were treated for 28 days with 250 mg/kg/day of nifedipine and lidocaine (0.3% and 1.5% w/w) rectal cream, a decrease from baseline in systolic blood pressure (-10 mm Hg), and diastolic blood pressure (-5 mm Hg) was noted.

Nifedipine:

Table 8 - LD50 in Animal Studies

Species	Dose Range (mg/kg)		LD ₅₀ (mg/kg)	
	Oral	Intravenous	Oral	Intravenous
Mouse	294-882	3-5	494 (421-572)*	4.2 (3.8-4.6)*
Rat	588-1323	10-25	1022 (950-1087)*	15.5 (13.7-17.5)*
Rabbit	100-500	1-4	250-500	2-3
Cat	50-250	0.5-8	100	0.5-8
Dog	250-2000	0.5-3	>250	2-3

* 95% confidence interval.

Lidocaine:

Table 9 - LD50 in Animal Studies

SPECIES	SEX	ROUTE	LD ₅₀ (mg/kg)
mice	F	i.v.	17.9
mice	F	i.p.	164
mice	F	i.m.	200
mice	M	i.m.	154
rat	F	i.v.	19.7
rat	M	i.v.	21.4
dog	M & F	i.m.	100
guinea pig	F	i.m.	73
guinea pig	M	i.m.	67
rabbit	M	i.m.	450

Chronic and subacute studies

Nifedipine and Lidocaine (0.3% and 1.5% w/w) rectal cream

Nifedipine and Lidocaine (0.3% and 1.5% w/w) rectal cream administered at 250 mg/kg/day for 28 days in rats caused a decrease in systolic blood pressure (13 mm Hg in male and 12 mm Hg in female) and diastolic blood pressure (9 mm Hg both in male and female).

Nifedipine

In rats, oral doses of 0.5 to 100 mg/kg/day nifedipine for 13 weeks did not induce significant adverse effects. Similar results were obtained in dogs treated with 0.5 to 50 mg/kg/day nifedipine for 13 weeks.

Lidocaine

In a study in dogs, mild transient convulsions were reported in one dog treated with 3 mg/kg for 21 days, with no drug related effect at the autopsy.

In a second study, dogs received a daily intravenous of 2.5, 5 or 10 mg/kg for 28 days: transient sedation, ataxia, head tremor, prostration and emesis were reported at 5 mg/kg. At the 10 mg/kg level, severe tremors, muscular weakness, ataxia, prostration and convulsions were reported (although

animals recovered within 5-10 minutes). No drug-related findings were present at the ECG, hemochemistry, or autopsy assessments. No overt symptoms were observed at 2.5 mg/kg dose.

In rats, daily intravenous doses of 1.5, 4.5 or 15.0 mg/kg were administered for 14 days. Overt effects were observed only at the 15.0 mg/kg level, including convulsions and death. Increased blood glucose levels were seen in male rats at all dose levels. At autopsy, no changes were attributed to drug treatment.

Carcinogenicity:

Nifedipine

Nifedipine was administered orally to dogs at dosages of 2.5, 20 and 100 mg/kg/day for 52 weeks. No indication of toxic damage caused by nifedipine was found.

In a 2-year study, nifedipine was administered orally to male and female rats in the diet at dosages of 5-9, 29-39, and 156-210 mg/kg/day. In the lowest dose group, nifedipine was without toxic effects. The higher dosage led to dose-dependent, significant weight losses. An increased mortality was found in the 156-210 mg/kg dose group, especially in the females. The pathological and anatomical examination of the dead animals showed a hypotonia or atonia of the musculature of the small intestine. An increase in the weight of the adrenal glands of male rats was also observed in this dose group. Histopathological examinations revealed no organ damage related to treatment.

At the end of the study, all rats were examined histopathologically with regards to tumorigenesis. Although the animals in the highest dose group showed no uncommon tumor incidences, this group was considered not suitable for comparison with the other treatment groups because of the high mortality rate. No significant difference were found between the controls and the remaining two treatment groups with respect to the frequency, nature and localisation of tumors.

Lidocaine

There are no available pre-clinical data assessing the carcinogenic toxicity of lidocaine.

The carcinogenicity of the metabolite 2,6-dimethylaniline was tested in rats.

A chronic oral toxicity study of the metabolite 2,6-dimethylaniline (0, 14, 45, 135 mg/kg) administered in feed to rats showed that there was a significantly greater incidence of nasal cavity tumors in male and female animals that had daily oral exposure to the highest dose of 2,6-dimethylaniline for 2 years. The lowest tumor-inducing dose tested in animals (135 mg/kg) corresponds to approximately 112 times the amount of 2,6-dimethylaniline to which a 50 kg subject would be exposed following the application of 6 g of Seaford Nifedipine and Lidocaine Hydrochloride Cream (0.3%/1.5% w/w) for 24 hours on the mucosa, assuming the highest theoretical extent of absorption of 100%, and 80% conversion to 2,6-dimethylaniline. Based on a yearly exposure (once daily dosing with 2,6-dimethylaniline in animals) and a 21-day course of treatment with 6 g per day of Seaford Nifedipine and Lidocaine Hydrochloride Cream in humans, the safety margins would be approximately 1955 times when comparing the exposure in animals to man.

Genotoxicity:

Nifedipine

In the Dominant Lethal test, the oral administration of nifedipine to mice at a dose of 100 mg/kg for 5 consecutive days did not affect fertility rate or post-implantation loss.

In the Micronucleus test, 2 doses of 50 mg/kg or 100 mg/kg nifedipine given orally to mice also did not

produce any mutagenic effect. Furthermore, the formation of erythrocytes was not impaired as shown by the polychromatic: normochromatic erythrocyte ratio.

In the Ames' Salmonella/microsome test, nifedipine at doses of up to 12500 µg per plate did not cause any bacterotoxic effects. Also, a dose-dependent and biologically relevant increase in the number of mutants to a level double that of the negative control was not noted.

Lidocaine

Genotoxicity tests with lidocaine showed no evidence of mutagenic potential.

A metabolite of lidocaine, 2,6-dimethylaniline, showed weak evidence of activity in some genotoxicity tests. In Chinese hamster ovary cells treated with 2,6-dimethylaniline at a dose of 301 mg/L, the results showed sister chromatid exchange with and without rat S9 metabolic activation. Also in Chinese hamster ovary cells treated with 2,6-dimethylaniline at a dose of 1200 mg/L, results showed that 2,6-dimethylaniline caused chromosomal aberrations with and without rat S9 metabolic activation. *In vivo*, the micronucleus test was performed in mice treated with one oral dose of 2,6-Dimethylaniline (350 mg/kg) or with three oral doses of 2,6-Dimethylaniline (75 and 375 mg/kg). 2,6-Dimethylaniline administration did not induce micronuclei in bone marrow erythrocytes of mice.

Reproductive and Developmental Toxicology:

Nifedipine

Male rats administered orally with nifedipine (0.571 mg/kg) for 30 days showed a decline in sperm count and decrease sperm motility. Following a 30 days recovery without administration of nifedipine, sperm count and motility recovered to levels comparable to controls.

Pregnant mice, rats and rabbits were treated orally with 10, 30 and 100 mg/kg nifedipine from day 6 to day 15 of gestation. In the mouse, at doses of 30 and 100 mg/kg, there was an increase in the number of fetal resorptions. Fetal malformations in the form of cleft palate and rib deformities occurred at all dose levels in a dose related fashion. (Cleft palate occurred in 5/218 controls, 13/190 at 10 mg/kg, 22/112 at 30 mg/kg and 3/3 at 100 mg/kg).

In the rat, the dose of 30 mg/kg was not toxic to pregnant dams, but caused reduced fetal weight and increased fetal loss. The dose of 100 mg/kg produced malformations in the fetuses from 20% of the mother animals. In a total of 11 fetuses, 10 showed malformation of the front or hind paws (ectrodactyly, oligodactyly and adactyly) and one developed a severe malformation of the sinciput.

In the rabbit, there was a dose-dependent anorexia and weight loss in mothers during the dosing period with oral nifedipine. At 30 and 100 mg/kg, reduced litter size and weight and increased fetal loss were evident.

Studies on pregnant rhesus monkeys with oral doses of 2 (1 animal) or 6 mg/kg/day (4 animals) with oral nifedipine revealed no teratogenic effects. The placentas were poorly developed in dosed animals.

Pre- and post-natal studies on rats with daily doses of 3, 10, 30 and 100 mg/kg showed that oral nifedipine caused significant prolongation of the gestation period at dosage of 10 mg/kg upwards and a decrease in litter size. The post-natal development of the newborn animals was impaired when doses of 30 mg/kg or more had been administered. All offspring in the 100 mg/kg group died. *Lidocaine*

Oral administration of lidocaine (500 mg/kg/day) to pregnant rats lowers embryo body weight at E21.

17 SUPPORTING PRODUCT MONOGRAPHS

XYLOCAINE® Ointment 5%, Submission control 237729, Product Monograph, Aspen Pharmacare Canada Inc., Oct 11, 2022

XYLOCARD®, IV Solution, 20 mg/mL), Submission control 246218, Product Monograph, Aspen Pharmacare Canada Inc., May 21, 2021

ADALAT® OROS®, oral tablets 20, 30, 60 mg. Submission control 198159, Product Monograph, Bayer Inc., Sept 29, 2016

PRO-NIFEDIPINE ER, tablets 30 mg. Submission control 283492, Product Monograph, Pro Doc Ltee, Feb 27, 2024

NIFEDIPINE, oral capsules 5, 10 mg. Submission control 271662, Product Monograph, AA Pharma Inc, Dec 01, 2023

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **SEAFORD NIFEDIPINE AND LIDOCAINE HYDROCHLORIDE CREAM**

Read this carefully before you start taking **Seaford Nifedipine and Lidocaine Hydrochloride Cream** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Seaford Nifedipine and Lidocaine Hydrochloride Cream** .

Serious Warnings and Precautions

Seaford Nifedipine and Lidocaine Hydrochloride Cream can cause a rare, but serious, blood disorder called methemoglobinemia. It can appear up to two hours after you use Seaford Nifedipine and Lidocaine Hydrochloride Cream. Stop using Seaford Nifedipine and Lidocaine Hydrochloride Cream and talk to your healthcare professional immediately if you get any of the following symptoms: weakness, confusion, headache, difficulty breathing, pale, grey or blue coloured skin.

What is Seaford Nifedipine and Lidocaine Hydrochloride Cream used for?

Seaford Nifedipine and Lidocaine Hydrochloride Cream is used in adults for the management of anal fissures that have not improved with the use of stool softeners and topical anesthetic agents. Fissures are usually caused by hard, dry bowel movements or loose, frequent bowel movements.

How does Seaford Nifedipine and Lidocaine Hydrochloride Cream work?

Seaford Nifedipine and Lidocaine Hydrochloride Cream contains two medicinal ingredients; nifedipine and lidocaine hydrochloride. Nifedipine relaxes the muscles around the anus. Lidocaine produces a temporary loss of feeling or numbness on the area where it is applied.

What are the ingredients in Seaford Nifedipine and Lidocaine Hydrochloride Cream?

Medicinal ingredients: nifedipine, lidocaine hydrochloride

Non-medicinal ingredients: cetostearyl alcohol – Type A, glycerol monostearate, macrogol stearate, medium chain triglycerides, propyl parahydroxybenzoate, propylene glycol, purified water, sodium methyl parahydroxybenzoate, white soft paraffin.

Seaford Nifedipine and Lidocaine Hydrochloride Cream comes in the following dosage forms:

Cream; 0.3% / 1.5% w/w, each gram of cream contains 3 mg of nifedipine and 15 mg of lidocaine hydrochloride.

Do not use Seaford Nifedipine and Lidocaine Hydrochloride Cream if:

- you are allergic to any of the following:
 - nifedipine
 - other dihydropyridines calcium antagonists, a calcium channel blocker used to treat high blood pressure and other heart problems
 - lidocaine
 - local anesthetics of the amide type
 - other components of the cream including any non-medicinal ingredients (see **What are the ingredients in Seaford Nifedipine and Lidocaine Hydrochloride Cream?**)

- you are pregnant, or planning to become pregnant
- you are breastfeeding. Nifedipine and lidocaine pass into breast milk.
- you have a blood disorder called methemoglobinemia that affects how your blood cells deliver oxygen to your cells and tissues
- you have a condition called glucose-6-phosphate dehydrogenase deficiency which causes your red blood cells to break down
- you have severe low blood pressure
- you have heart failure
- you are in cardiogenic shock, a condition where your heart suddenly cannot pump enough blood and oxygen to the brain and other vital organs
- you have had a recent heart attack
- you have unstable angina, sudden chest pain that occurs at rest and gets increasingly worse
- you are taking diltiazem, a calcium channel blocker used to lower blood pressure

Do not use **Seaford Nifedipine and Lidocaine Hydrochloride Cream** in large quantities.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you use Seaford Nifedipine and Lidocaine Hydrochloride Cream. Talk about any health conditions or problems you may have, including if you:

- have inflammation, bruising, an infection or any other injury in the anal or rectal area. Using Seaford Nifedipine and Lidocaine Hydrochloride Cream in these cases may cause you to absorb too much medicine into your body.
- have diabetes
- have kidney, or liver problems
- have, or have a history of, low blood pressure or if you are taking medications that are known to lower blood pressure
- have heart problems, including:
 - a history of severe heart failure or heart disease
 - aortic stenosis, a narrowing of a valve in your heart
 - bradycardia, a slower than normal heart rate
 - an irregular heartbeat
 - chest pain (angina)
- have a history of cerebrovascular insufficiency, a problem with blood flow to your brain
- are going to have surgery. Tell the healthcare professional that will be performing the surgery that you are using Seaford Nifedipine and Lidocaine Hydrochloride Cream.
- are a man and have been repeatedly unsuccessful at fathering a child by in vitro fertilization
- are 65 years of age or older

Other warnings you should know about:

Avoid contact with the eyes. If you get Seaford Nifedipine and Lidocaine Hydrochloride Cream in or near your eyes, rinse thoroughly with water.

Talk to your healthcare professional if your condition does not improve while you are using Seaford Nifedipine and Lidocaine Hydrochloride Cream or if it gets worse.

Serious allergic reactions: Seaford Nifedipine and Lidocaine Hydrochloride Cream can cause serious allergic reactions. These reactions can be delayed, happening hours or days after using Seaford

Nifedipine and Lidocaine Hydrochloride Cream. Stop using Seaford Nifedipine and Lidocaine Hydrochloride Cream and get immediate medical help if you have a serious allergic reaction. See the **Serious side effects and what to do about them** table, below, for more information on this and other serious side effects.

Skin reactions: Seaford Nifedipine and Lidocaine Hydrochloride Cream contains two non-medicinal ingredients, propylene glycol and cetostearyl alcohol, that can cause skin reactions such as dermatitis. Talk to your healthcare professional if you get a skin reaction while using Seaford Nifedipine and Lidocaine Hydrochloride Cream.

Blood tests and monitoring: Your healthcare professional will do blood tests while you are using Seaford Nifedipine and Lidocaine Hydrochloride Cream. They will also check your blood pressure before you start using Seaford Nifedipine and Lidocaine Hydrochloride Cream and periodically during treatment. Your healthcare professional will decide when to perform these tests and will interpret the results.

Driving and using machines: Wait until you know how you respond to Seaford Nifedipine and Lidocaine Hydrochloride Cream before driving or using potentially dangerous machinery.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with Seaford Nifedipine and Lidocaine Hydrochloride Cream :

- medicines used to treat high blood pressure and chest pain such as nitroglycerin, nitroprusside, calcium channel blockers (e.g. amlodipine, clevidipine, felodipine, isradipine, nimodine, diltiazem), beta blockers (e.g. atenolol, metoprolol, propranolol)
- medicines used to reduce the amount of acid in your stomach such as cimetidine, cisapride, ranitidine
- medicines used to treat heart problems and irregular heartbeat such as digoxin, quinidine, propafenone, mexiletine, amiodarone
- medicines used to treat fungal infections, with a name ending in “azole”, such as ketoconazole, itraconazole, fluconazole
- medicines used to treat or prevent blood clots such as warfarin, coumadin
- medicines used to suppress the immune system such as tacrolimus, cyclosporine
- medicines used to treat depression such as fluoxetine, nefazodone, imipramine
- medicines used to treat bacterial infections such as erythromycin, clarithromycin, cyclosporine, quinupristin/dalfopristin, rifampicin, sulfonamides, nitrofurantoin, dapsone
- medicines used to treat HIV/AIDS such as amprenavir, indinavir, nelfinavir, ritonavir, saquinavir
- medicines used to treat seizures such as phenobarbital, phenytoin, valproic acid, carbamazepine
- medicines used to treat or prevent malaria such as primaquine, quinine, chloroquine
- acetaminophen, used to treat pain and fever
- benzodiazepines, used to treat anxiety, seizures and insomnia
- fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), used to treat obsessive-compulsive disorder (OCD)
- local anesthetics used to numb the skin and provide pain relief such as benzocaine
- para-aminosalicylic acid, used to treat tuberculosis
- St. John’s Wort, an herbal medicine used to treat depression
- terfenadine, used to treat allergies

- theophylline, used to treat breathing problems
- grapefruit or grapefruit juice. Do not eat grapefruit or drink grapefruit juice while you are using Seaford Nifedipine and Lidocaine Hydrochloride Cream.

How to use Seaford Nifedipine and Lidocaine Hydrochloride Cream:

- Use Seaford Nifedipine and Lidocaine Hydrochloride Cream exactly as your healthcare professional has told you. Do not change your dose or stop using Seaford Nifedipine and Lidocaine Hydrochloride Cream without talking to your healthcare professional. Do not use more than prescribed or use it more often as this can cause serious side effects.
- Do not swallow. Seaford Nifedipine and Lidocaine Hydrochloride Cream is only to be used inside and, if needed, around the anus (perianally).
- Thoroughly clean and dry the anal/rectal area.
- Lie down in a comfortable place and tilt your body towards the left.
- Remove the cap from the tube. Screw on the applicator (cannula) with the cover.
- Release a small amount of cream to lubricate the outer part of the applicator.
- Insert the tip of the applicator into the anus (up to 1 cm) and gently squeeze the tube from the bottom to release the cream.
- Release the cream until the next marking on the tube is reached. Each marking will administer approximately 2.5g – 3g of cream.
 - For 30 g tubes: There are 10 markings on the side of the tube that are 1 cm apart.
 - For 10 g tubes: There are 3 markings on the side of the tube that are 1.7 cm apart.
- Remain on your left side for 3 - 5 minutes after application.
- Take the applicator off of the tube and rinse it with hot water and soap.
- When finished using, close the tube with the cap.
- Wash your hands after using the medicine.

Usual dose:

30 g tube - Apply 2.5 – 3 g of Seaford Nifedipine and Lidocaine Hydrochloride Cream inside (and if needed, around the anus) twice daily for 3 weeks. The 1 cm markings on the side of tube indicate one dose.

10 g tube - Apply 2.5 – 3 g of Seaford Nifedipine and Lidocaine Hydrochloride Cream inside (and if needed, around the anus) twice daily. The treatment should be continued for 3 weeks. The 1.7 cm markings on the side of tube indicate one dose.

Overdose:

If you think you, or a person you are caring for, have used too much Seaford Nifedipine and Lidocaine Hydrochloride Cream, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you forgot a dose of Seaford Nifedipine and Lidocaine Hydrochloride Cream at the usual time, do not use a double dose. Skip the missed dose and wait until it is time for your next dose. If you are unsure talk to your healthcare professional.

What are possible side effects from using Seaford Nifedipine and Lidocaine Hydrochloride Cream?

These are not all the possible side effects you may have when using Seaford Nifedipine and Lidocaine Hydrochloride Cream. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- headache
- nausea, vomiting
- constipation
- hot flashes
- bleeding from the rectum when having a bowel movement
- fecal incontinence (inability to hold stool until you get to a toilet)

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
UNCOMMON			
Local reactions at the application site: pain, burning sensation, spasms, itching, rash, inflammation, accumulation of large amounts of blood in the treated area		✓	
High blood pressure: shortness of breath, fatigue, dizziness or fainting, chest pain or pressure, swelling in your ankles and legs, bluish colour to your lips and skin, racing pulse or heart palpitations			✓
RARE			
Methemoglobinemia (rare blood disorder): weakness, confusion, headache, difficulty breathing, pale, grey or blue coloured skin			✓
NOT KNOWN			
Low blood pressure: dizziness, fainting, light-headedness, blurred vision, nausea, vomiting, fatigue (may occur when you go from lying or sitting to standing up)		✓	
Allergic reactions: difficulty swallowing or breathing, wheezing, nausea, vomiting, hives or rash, swelling of the face, lips, tongue or throat			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at 15°C to 25°C. Do not freeze. Protect from light. Keep out of reach and sight of children.

If you want more information about Seaford Nifedipine and Lidocaine Hydrochloride Cream:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website (Seaford.ca) or by calling 1-888-292-3192

This leaflet was prepared by Seaford Pharmaceuticals Inc.

Last Revised JUN 13, 2025